A new wave of antipsychotics could improve patient adherence. The race to corner this large projected market is already getting tight.
NORTH CHICAGO, Ill., Aug. 1, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has completed its acquisition of Cerevel Therapeutics (NASDAQ: CERE). With the completion of the acquisition, Cerevel is now part of AbbVie.
Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study
Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-3 adjunctive trial, demonstrating a statistically significant increase in total on time without troublesome dyskinesia compared with...
Cerevel Therapeutics is lower by 3.66% Tuesday In Premarket Trading
Dec 6 (Reuters) - AbbVie (ABBV.N) said on Wednesday it would buy Cerevel Therapeutics (CERE.O), a developer of drugs for neurological conditions, for about $8.7 billion in a bid to replace revenue as its arthritis drug Humira faces a raft of new competition.
Event will focus on tavapadon, a D1/D5 partial agonist in Phase 3 development for the treatment of Parkinson™s disease Live webcast scheduled for Monday, December 11 from 10:00 to 11:30 a.m. ET ...
Cerevel to Present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference
Cerevel Therapeutics Announces Third Quarter 2020 Financial Results
CAMBRIDGE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, today announced...